Published: May 2020 | Report Code: LS12014 | Available Format: PDF | Pages: 160
The global carrier screening market valued $1,303.6 million in 2019, and it is predicted to advance with a CAGR of 10.9% during the forecast period (2020–2030). The increasing prevalence of genetic diseases, rising availability and affordability of tests, and surging number of advanced product launches are the major factors helping the market grow.
The expanded carrier screening bifurcation, under segmentation by type, dominated the carrier screening market in 2019. This is attributed to the wide use of next-generation sequencing (NGS) and other high-throughput technologies for the purpose, around the world. Additionally, the expanded approach to carrier screening allows for the testing for multiple diseases at once.
Till 2030, the highest CAGR in the carrier screening market would be witnessed by the deoxyribonucleic acid (DNA) sequencing classification, under the technology segment, owing to the low cost of the technology and the fact that using it doesn’t require a high expertise in the bioinformatics field. Further, in recent years, DNA sequencing has been integrated with numerous user-friendly tools, which has made the screening process quite simple.
The cystic fibrosis division, based on application, held the largest share in the carrier screening market during the historical period (2014–2019). This has been a result of the increasing incidence of this disease in Europe and North America. Further, people are also becoming aware about this health issue and the importance of it being diagnosed early, which is pushing the demand for genetic testing for this condition.
During the forecast period, the hospitals category, on the basis of end user, is expected to observe the fastest growth in the carrier screening market, on account of the heavy usage of genetic disease testing kits by experienced professionals in such medical settings. Moreover, an increasing number of policies and insurance firms are offering reimbursements for such tests, which is another reason for the advance of this category.
North America was the largest carrier screening market in 2019, and the situation would be the same over the forecast period. This is credited to the high rate of tests to determine whether a person is at risk or a carrier of any genetic disorder. Other reasons for the dominance of the continent on the industry are its advanced healthcare infrastructure and the existence of numerous established market players.
The key trend in the carrier screening market is the acquisition of the companies providing solutions for the tests, by larger biotechnology firms. For instance, in January 2020, Quest Diagnostics Inc. acquired Blueprint Genetics, a specialist in genetic testing solutions. With this move, Quest is aiming to gain expertise in genetic and rare diseases, pharmaceutical drug research and development (R&D), and ways to improve patient care. In the same vein, in January 2019, ArcherDX Inc., a company engaged in the molecular technology field, acquired Baby Genes Inc., a provider of carrier screening services. As part of the agreement, while Baby Genes will function as a wholly owned subsidiary of ArcherDX, it markets its existing suite of neonatal and carrier screening genetic testing services under its own brand.
The major growth driver for the carrier screening market is the rising prevalence of genetic diseases, as the risk and severity of the disorder depend on the parent’s carrier status and ancestors. To detect the risk of such diseases early, especially cystic fibrosis, fragile X syndrome, and spinal muscular atrophy (SMA), the American College of Obstetricians and Gynecologists recommends testing all pregnant women and those considering motherhood in the future. As genetic diseases account for a high infant mortality and congenital abnormality rate, parents are becoming increasingly concerned for the future generation. Thus, they are going for genetic testing prior to considering subsequent steps, such as in vitro fertilization (IVF) and preimplantation genetic diagnosis (PGD).
In recent years, carrier screening market players have launched an array of products and services, in order to strengthen their position in the industry.
For instance, in February 2020, a new NGS-based test kit was launched by Thermo Fisher Scientific Inc., to enable researchers in the reproductive health field to better analyze a wide range of key genetic markers, with an end-to-end workflow. The consolidation of a multi-platform expanded carrier screening approach into a single solution, which helps the company expand its portfolio of reproductive health research services, is the key feature of the Ion Torrent CarrierSeq ECS Kit developed for the Ion GeneStudio S5 System.
In the same vein, in August 2018, Sema4 unveiled an enhanced version of its expanded carrier screen and the Noninvasive Prenatal Select tests for the field of reproductive health. Driven by an informatics approach, these two products are an extension of the company’s portfolio.
The major players in the global carrier screening market are Invitae Corporation, Illumina Inc., Thermo Fisher Scientific Inc., Otogenetics Corporation, Myriad Genetics Inc., Luminex Corporation, Gene By Gene Ltd., MedGenome Inc., Natera Inc., Laboratory Corporation of America Holdings, and Mount Sinai Genomics Inc.
The carrier screening market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.
Based on Type
Based on Application
Based on Technology
Based on End User
The carrier screening market is expected to grow with a CAGR of 10.9% during 2020–2030.
The global carrier screening market is fragmented in nature, due to the presence of a number of players, the majority of whom are based in the U.S.
The market growth in the “hospital” category is primarily attributed to the high adoption rate of advanced products and kits at these places to screen patients under the supervision of trained healthcare professionals.
Laboratory Corporation of America Holdings, Invitae Corporation, Natera Inc., and Myriad Genetics Inc. are some of the major players operating in the carrier screening market.
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws